Dr. John J. Lee, M.D.
Allergy & Immunology (Allergy & Immunology Physician)
At a glance
- Medical school
- New York University School of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: New York University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
MA license 224048
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Children's Hospital Pediatric Associates, Inc (328 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 1 companies. The companies reported $162,532 in research payments for these studies, mostly to the institutions running them.
- A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06693531 - A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05831176 - Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
Regeneron Pharmaceuticals, Inc. · Completed · NCT04394351 - Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)
Regeneron Pharmaceuticals, Inc. · Completed · NCT06593600
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.